This story comes to us from Bioenterprise, a partner in the Agri-Technology Commercialization Centre.
AbCelex-logoMississauga – Each year, millions of North Americans fall ill after eating chicken, thanks to a corkscrew-shaped bacteria called Campylobacter.
According to AbCelex’s CEO, Dr. Babaei, the solution could lie in a quirk of camel biology.
In 1993, scientists made an intriguing discovery. Although mammals around the world have the same basic kind of antibodies, it turns out that members of the camel family also have a second type — one that is smaller, more stable and cheaper to produce.
Dr. Saeid Babaei and his business partner, Dr. Ali Riazi, saw big potential to use these antibodies or their derivatives in livestock. The pair founded AbCelex Technologies Inc., negotiated an exclusive worldwide license from National Research Council of Canada and set to work creating small antibody fragments— so-‐called “nanobodies” — to inactivate Campylobacter.
Their solution can’t come soon enough.
“Campylobacter is a number one cause of foodborne illness in the Western world,” explains Babaei.
More than half of the raw poultry sold in the U.S. contains this disease-‐causing bacteria. In the U.K., it’s 65 per cent.
The AbCelex founders knew that any cost-‐effective treatment had to be delivered in feed. That means engineering nanobodies that can withstand the high temperatures used to process animal feed and the low pH and enzymes in the digestive system.
In the course of the last three years, AbCelex has made a tremendous progress in advancing their platform technology through the Campylobacter program in broilers.
Currently, they’re developing methods to increase effectiveness of their products against various pathogenic strains of Campylobacter, as well as being able to produce high volumes of their product at low costs.
Click here to see more...